Proven efficiency, giving you the freedom to do more
With STI rates on the rise, cobas® CT/NG provides a solution to meet the growing demand for CT/NG Testing, delivering exceptional assay performance, providing broader information for improved patient care decisions, and enabling simplicity and flexibility to support varying throughput and workflow requirements.
Exceptional assay performance
Broader information for improved patient care decisions
Studies have shown that as high as 50% of infections may be missed in high risk male populations where patients were only tested using traditional urogenital specimens.1
Simplicity and flexibility to meet varying throughput and workflow requirements
cobas® CT/NG for use on the cobas® 6800/8800 Systems is an automated, qualitative in vitro nucleic diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, endocervical swab specimens, oropharyngeal (throat) and anorectal swab specimens, all collected in cobas® PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt® Solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.
1. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014,Recommendations and Reports / Vol. 63 / No. 2 March 14, 2014, pgs 10-11.